Ovid Therapeutics (OVID) delivered earnings and revenue surprises of -5.56% and 10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the...
OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizuresData demonstrate...
Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor, and initiating Phase 1 trials in...
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...
Ovid executing on its strategy to build a leading epilepsy pipelineOV329 expected to enter the clinic in 2022Organization reshaped to reduce personnel by...
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...
– Ovid to License Gaboxadol to Healx – – Healx to Explore Gaboxadol in Combination Therapies for Fragile X, Other Indications – NEW YORK, N.Y. and...
Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic...